Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain

BACKGROUND: Overactive bladder (OAB) is associated with high healthcare costs, which may be partially driven by drug treatment. There is little comparative data on antimuscarinic drugs with respect to resource use and costs. This study was conducted to address this gap and the growing need for natur...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Sicras-Mainar, Antoni, Rejas, Javier, Navarro-Artieda, Ruth, Aguado-Jodar, Alba, Ruiz-Torrejón, Amador, Ibáñez-Nolla, Jordi, Kvasz, Marion
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2013
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4015546/
https://ncbi.nlm.nih.gov/pubmed/24144225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2490-13-51
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge